Heerspink HDL, et al. Effects of semaglutide on kidney parameters in patients with obesity and nondiabetic CKD [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR102. doi: 10.1681/ASN.20242wv2xw41

• PubMed
Heerspink HDL, Effects of semaglutide on kidney parameters in patients with obesity and nondiabetic CKD [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR102. doi: 10.1681/ASN.20242wv2xw41)| false
• Search Google Scholar
• Export Citation

Tuttle KR, et al. Semaglutide reduced risks of major kidney outcomes irrespective of CKD severity in the FLOW trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR93. doi: 10.1681/ASN.2024bjyvcgfe

• PubMed
Tuttle KR, Semaglutide reduced risks of major kidney outcomes irrespective of CKD severity in the FLOW trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR93. doi: 10.1681/ASN.2024bjyvcgfe)| false
• Search Google Scholar
• Export Citation

Mann JFE, et al. Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med 2024; 30:2849–2856. doi: 10.1038/s41591-024-03133-0

• PubMed
Mann JFE, Effects of semaglutide with and without concomitant SGLT2 inhibitor use in participants with type 2 diabetes and chronic kidney disease in the FLOW trial. Nat Med 2024; 30:2849–2856. doi: 10.1038/s41591-024-03133-0)| false
• Search Google Scholar
• Export Citation

Herrington WG, et al. Long-term effects of empagliflozin in CKD [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR103. doi: 10.1681/ASN.20240jw7xqsh

• PubMed
Herrington WG, Long-term effects of empagliflozin in CKD [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR103. doi: 10.1681/ASN.20240jw7xqsh)| false
• Search Google Scholar
• Export Citation

Hung CC, et al. Efficacy and safety of dapagliflozin in patients with CKD stages 4–5 [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR96. doi: 10.1681/ASN.2024aa8zcvk

• PubMed
Hung CC, Efficacy and safety of dapagliflozin in patients with CKD stages 4–5 [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR96. doi: 10.1681/ASN.2024aa8zcvk)| false
• Search Google Scholar
• Export Citation

Dember LM, et al. Pain coping skills training for patients receiving hemodialysis: The HOPE consortium randomized clinical trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR94. doi: 10.1681/ASN.2024meh73bqt

• PubMed
Dember LM, Pain coping skills training for patients receiving hemodialysis: The HOPE consortium randomized clinical trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR94. doi: 10.1681/ASN.2024meh73bqt)| false
• Search Google Scholar
• Export Citation

Liu B-C, et al. Efficacy and safety of HSK21542 for moderate-to-severe CKD-associated pruritus: A phase 3 trial in hemodialysis patients [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR104. doi: 10.1681/ASN.2024bmrj47b4

• PubMed
Liu B-C, Efficacy and safety of HSK21542 for moderate-to-severe CKD-associated pruritus: A phase 3 trial in hemodialysis patients [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR104. doi: 10.1681/ASN.2024bmrj47b4)| false
• Search Google Scholar
• Export Citation

McCausland FR, et al. Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR100. doi: 10.1681/ASN.2024jpj2c3rq

• PubMed
McCausland FR, Finerenone and kidney outcomes in patients with heart failure: The FINEARTS-HF trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR100. doi: 10.1681/ASN.2024jpj2c3rq)| false
• Search Google Scholar
• Export Citation

Aklilu AM, et al. Personalized recommendations for AKI using a kidney action team: A multicenter randomized controlled trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR101. doi: 10.1681/ASN.2024gjjnbwvc

• PubMed
Aklilu AM, Personalized recommendations for AKI using a kidney action team: A multicenter randomized controlled trial [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR101. doi: 10.1681/ASN.2024gjjnbwvc)| false
• Search Google Scholar
• Export Citation

Liu F, et al. Efficacy and safety of Tac or MMF for children with steroid-sensitive but frequent relapse or steroid-dependent nephrotic syndrome: A nationwide, multicentre randomized study [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR105. doi: 10.1681/ASN.2024r9krgt8d

• PubMed
Liu F, Efficacy and safety of Tac or MMF for children with steroid-sensitive but frequent relapse or steroid-dependent nephrotic syndrome: A nationwide, multicentre randomized study [Abstract]. J Am Soc Nephrol 2024; 35(10S):FR-OR105. doi: 10.1681/ASN.2024r9krgt8d)| false
• Search Google Scholar
• Export Citation

Refardt J, et al. Impact of targeted hyponatremia correction on 30-day mortality and rehospitalization rate [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR91. doi: 10.1681/ASN.20246g8dmygt

• PubMed
Refardt J, Impact of targeted hyponatremia correction on 30-day mortality and rehospitalization rate [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR91. doi: 10.1681/ASN.20246g8dmygt)| false
• Search Google Scholar
• Export Citation

Nester CM, et al. VALIANT: A randomized, multicenter, double-blind, placebo (PBO)-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR92. doi: 10.1681/ASN.2024qdwvz5bg

• PubMed
Nester CM, VALIANT: A randomized, multicenter, double-blind, placebo (PBO)-controlled, phase 3 trial of pegcetacoplan for patients with native or post-transplant recurrent glomerulopathy (C3G) or primary immune complex membranoproliferative glomerulonephritis (IC-MPGN) [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR92. doi: 10.1681/ASN.2024qdwvz5bg)| false
• Search Google Scholar
• Export Citation

Hussain MA, et al. Prospective randomized trial of Humacyte's acellular tissue engineered vessel vs. autologous arteriovenous fistula for hemodialysis access [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR95. doi: 10.1681/ASN.2024y8139maa

• PubMed
Hussain MA, Prospective randomized trial of Humacyte's acellular tissue engineered vessel vs. autologous arteriovenous fistula for hemodialysis access [Abstract]. J Am Soc Nephrol 2024; 35(10S):SA-OR95. doi: 10.1681/ASN.2024y8139maa)| false
• Search Google Scholar
• Export Citation